Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Rhea-AI Summary
Molecular Partners (NASDAQ:MOLN), a clinical-stage biotech focused on DARPin therapeutics, will participate in TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30am ET.
The fireside chat will be webcast and accessible via the company’s website under the investors tab.
Positive
- None.
Negative
- None.
News Market Reaction – MOLN
In the May 27 session, MOLN declined 0.25%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 results, pipeline | Positive | -1.0% | Reported Q1 2026 financials and initiation of MP0712 and MP0317 studies. |
| May 04 | Conference presentations | Positive | +3.9% | Announced multiple oral presentations for DLL3-targeting Radio-DARPin MP0712. |
| May 01 | Phase 1 data | Positive | +0.2% | Published Phase 1 MP0317 data in Nature Cancer with favorable safety profile. |
| Apr 19 | AACR 2026 posters | Positive | +4.9% | Presented preclinical and early clinical data for MP0632 and MP0712 at AACR. |
| Apr 14 | AGM, governance | Neutral | +1.4% | AGM approved all proposals and elected a new board member despite reported losses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and conference updates have often coincided with modestly positive price moves, while earnings-related news saw a small negative reaction.
Over the past months, Molecular Partners reported Q1 2026 results with cash of CHF 79 million and runway into late 2027 on May 12, 2026, which saw a slightly negative reaction. Earlier in May, conference and publication news around MP0712 and MP0317 on May 4 and May 1 led to small gains. AACR 2026 poster presentations on April 19 also aligned with a stronger positive move. The AGM outcomes on April 14 were followed by a modest uptick, suggesting investors have responded constructively to scientific and governance updates.
Key Terms
darPin therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in the following upcoming investor conference.
TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA:
- Fireside chat on Wednesday, May 27, 2026 beginning at 11:30am ET
The event will be webcast and available on the Molecular Partners website, under the investors tab.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs.
For further details, please contact:
Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
